INDIA

KLab has 500 Medical representatives with 80 first line manager and 36 second line manager who cover 100000 Doctors, 56000 Pharmacies and 1200 Stockists in India every month.

KLab has launched four speciality divisions operating in different therapeutic areas, to enable focus on maximum new product launches. KLab focuses on Gastroenterologists, General Physicians, Orthopaedics, Surgeons, Paediatricians, Diabetologists, Cardiologists Chest Physicians, Gynaecologists etc

KLab has 24 Specialty Sales Representatives who are focusing only on all the oncologists and oncology institutes within the India.

KLab’s major sales are from patented products from in-house R&D. Cefi-XL our patented antibiotic combination is the No.1 launched new product in India in last 2 years as per July 2006 IMS report (Now sold to NPIL).

KLab has over 1100 employees. The sales force comprises around 600 persons

INTERNATIONAL

KLab started its global operations in regulated and non-regulated markets for its APIs and Pharma formulations.

KLab has presence in 22 countries having registered more than 150 products and more than 700 products are under registration.

More Details

DOMESTIC DIVISIONS

KLab has launched three specialty divisions operating in different therapeutic areas
. Argon

. Radon

. Oncure

The individual is at the heart of our creative process. We identify innovative individuals and partner with them.

Vacancies

Current openings

WHO-GMP Approved manufacturing facilities

WHO-GMP Approved manufacturing facilities for Oncology, General tablets and cephalosporin.

Markets

Regulated Markets
(USA, EUROPE)
Non-Regulated
(SOUTH EAST, ASIA, AFRICA, LATIN
AMERICA, CIS ETC)